Digital Banking Platform Market Disruptions: The $15.77 Billion Opportunity Vendors Can't Afford to Miss
Digital Banking Platform Market Set for Explosive Growth, Projected to Reach $15.77 Billion by 2030
MIDDLETON, Mass., April 16, 2025 /PRNewswire/ -- QKS Group, a premier market intelligence and advisory firm, has unveiled its latest comprehensive analysis of the global Digital Banking Platform Market, providing crucial insights for industry leaders aiming to capitalize on this rapidly evolving segment. The newly released reports- 'Market Share: Digital Banking Platform, 2024, Worldwide & Regional Report' and 'Market Forecast: Digital Banking Platform (AMR), 2025-2030, Worldwide & Regional Report' - reveal a projected market valuation of $15.77 billion by 2030, growing at a CAGR of 15.24% from 2025 to 2030. This analysis equips businesses with the strategic intelligence needed to navigate the dynamic Digital Banking landscape and make informed decisions as the market scales new heights.
The Next Growth Frontier in Digital Banking Platform
Digital Banking Platforms are redefining how financial institutions deliver services, engage customers, and scale innovation. These platforms provide the foundational infrastructure for banks and credit unions to offer omnichannel experiences, personalized financial insights, and real-time transactions across retail, corporate, and SME segments. As digital-native challengers gain traction and customer expectations evolve rapidly, traditional institutions are embracing cloud-native, API-first digital banking platforms to accelerate modernization, reduce operational friction, and drive continuous innovation.
According to VVVD Akhilesh, Senior Analyst at QKS Group, "The evolution of Digital Banking Platforms marks a pivotal moment for the financial services industry. As customer behavior shifts toward hyper-personalized, real-time engagement, banks can no longer afford legacy inertia. The winners will be those who embrace composable architecture, AI-driven insights, and open ecosystem integration, not as future goals, but as immediate imperatives. The Digital Banking Platform is no longer just IT infrastructure; it is the bank's competitive core."
Key Market Insights from QKS Group's Report
Global and Regional Market Analysis: An in-depth examination of worldwide and regional digital banking adoption trends, competitive landscapes, and future growth projections.
Competitive Benchmarking: A comparative analysis of top digital banking platform vendors, their market positioning, and strategic differentiators.
Industry Adoption Trends: Insights into which sectors are investing most heavily in digital banking platform and why.
Technology Disruption & AI's Role: AI, cloud-native architecture, and API orchestration are driving a fundamental shift in digital banking. Banks are leveraging AI to deliver predictive financial services, automate customer interactions, and enable real-time fraud detection. At the same time, microservices and low-code capabilities are empowering faster product rollouts, ecosystem partnerships, and hyper-scalable infrastructures. These innovations are not just optimizing operations, they're redefining what it means to be a digital-first bank.
Market Leaders & Competitive Landscape
The report covers key industry players, including Alkami Technology, Avaloq, Backbase, Bottomline Technologies, BPC, Coconet, Codebase Technologies, CR2, Data Action, Data Center Inc, Edgeverve, Finastra, Fisa Group, Fiserv, ieDigital, Intellect Design Arena, Kiya.ai, Mambu, Oracle, Sandstone Technology, Silverlake Axis, Sopra Banking Software, Tagit, TCS, Thought Machine, Ultradata, and Veritran.
Why This Matters for AMR Vendors
For CEOs, CMOs, and Chief Product Officers of digital banking solution providers, this is a critical inflection point. The demand for hyper-agile, secure, and intelligent digital banking experiences is not just growing, it's being expected. Vendors must go beyond feature parity and focus on delivering platforms that are cloud-native, integration-ready, and built for adaptability. Offering composable banking, real-time analytics, and regulatory agility will be key to capturing mindshare and wallet share in a fiercely competitive, rapidly evolving market.
Get Access to Exclusive Market Insights (single report or subscription offering)
Market Share: Digital Banking Platform, 2024, Worldwide https://qksgroup.com/market-research/market-share-digital-banking-platforms-2024-worldwide-2472
Market Forecast: Digital Banking Platform (AMR), 2025-2030, Worldwidehttps://qksgroup.com/market-research/market-forecast-digital-banking-platforms-2025-2030-worldwide-2276
The comprehensive research package includes:
Most Comprehensive Market Forecast Analysis: A separate market forecast report for each of the regions, including North America, Asia Pacific, European Union, MEA, Latin America
Unmatched Competitive Analysis: A separate market share report for each of the regions, including North America, Asia Pacific, European Union, MEA, Latin America
QKS TrendsNXT on Digital Banking Platform Market
QKS TAMSAM Insights report on Digital Banking Platform Market
Exclusive Analyst Advisory Sessions for strategic decision making and validation
About QKS Group
QKS Group, formerly Quadrant Knowledge Solutions, is a leading global advisory and research firm, dedicated to empowering technology innovators to accelerate their growth journeys and enable technology adopters to achieve their digital transformation objectives.
Click below to learn more about Competitive Intelligence Service: https://www.youtube.com/watch?v=bhUQYdKd90A
To gain access to the full market insights, growth forecasts, and competitive analysis, Connect: Shraddha Roy PR & Media RelationsQKS GroupRegus Business Center35 Village Road, Suite 100,Middleton Massachusetts 01949United StatesEmail: shraddha.r@qksgroup.comContent Source: https://qksgroup.com/newsroom/digital-banking-platform-market-disruptions-the-15-77-billion-opportunity-vendors-can-t-afford-to-miss-1055Connect with us on LinkedIn- https://www.linkedin.com/company/qksgroup/
Logo: https://mma.prnewswire.com/media/2501519/QKS_Group_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/digital-banking-platform-market-disruptions-the-15-77-billion-opportunity-vendors-cant-afford-to-miss-302430337.html
SOURCE QKS Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034) Due to the Advancements in Targeted Therapies
The follicular lymphoma market is expanding due to several factors. Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. Additionally, the rising number of clinical trials focused on the different treatment options for follicular lymphoma is a significant driver of its market's expansion. LAS VEGAS, June 4, 2025 /PRNewswire/ -- Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node enlargement, involvement of the bone marrow, and an enlarged spleen, while extranodal manifestations are relatively rare. As of 2024, approximately 35,000 cases of follicular lymphoma have been diagnosed across the 7MM, with both males and females having equal chances of getting the disease. First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized disease, radiotherapy (RT) alone or in combination with immunochemotherapy is commonly used. RT alone may also be an option for localized relapses. Learn more about follicular lymphoma treatment guidelines @ Follicular Lymphoma Treatment Market The follicular lymphoma treatment landscape is broad and continuously evolving, offering multiple options for both newly diagnosed and relapsed/refractory (R/R) cases. Rituximab is the primary treatment option across the lines. It takes the highest market share as well as patient share. The availability of rituximab biosimilars has enhanced accessibility and affordability, maintaining its importance in managing the disease. Apart from rituximab, GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a key component in first-line treatment strategies. Its effectiveness in both treatment-naïve and relapsed patients has reinforced its central role in clinical practice. LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults with R/R follicular lymphoma who have already received two or more prior treatments. Approved in 2023, LUNSUMIO has already captured ~10% patient share in the third line of therapy. Furthermore, the future approvals in earlier lines can boost its market share. Multiple targeted therapies are making significant contributions. TAZVERIK (tazemetostat), an EZH2 inhibitor, provides a precision medicine approach for patients with specific genetic mutations. BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, although primarily approved for other B-cell cancers, also plays a role in follicular lymphoma treatment. Recent approvals have further expanded the arsenal, including EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, as well as CAR T-cell therapies such as KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel). These innovative immunotherapies are showing encouraging outcomes, particularly in the R/R setting, and are poised to reshape the therapeutic approach to follicular lymphoma by offering deeper and potentially long-lasting remissions. Find out more on FDA-approved follicular lymphoma treatment @ Follicular Lymphoma Drugs Market While ongoing research continues to explore new treatments, many approved therapies are already making a significant impact in the follicular lymphoma treatment landscape. The forecast period (2024–2034) is expected to bring further advancements, with emerging therapies enhancing existing treatment options. As healthcare spending continues to increase worldwide, the Follicular lymphoma treatment space is anticipated to see a positive shift, with more accessible and effective therapies becoming available to patients in need. Numerous drugs are currently in development for the treatment of follicular lymphoma, including promising therapies like Zilovertamab Vedotin (Merck Sharp and Dohme), CALQUENCE (acalabrutinib) (AstraZeneca), CTX112 (CRISPR Therapeutics), BGB-16673 (BeiGene), NKTR-255 (Nektar Therapeutics), NVG-111 (NovalGen), AS-1763 (docirbrutinib) (Carna Biosciences), Cemacabtagene Ansegedleucel (ALLO-501) (Allogene Therapeutics), Abexinostat (Xynomic Pharmaceuticals), Golcadomide (Bristol-Myers Squibb), MONJUVI (tafasitamab) (Incyte Corporation), AZD0486 (AstraZeneca), and others, which are set to launch in the 7MM during the forecast period (2024–2034). Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Therapy MONJUVI (tafasitamab) is a humanized monoclonal antibody that targets CD19 and has been engineered with an Fc domain to enhance cytolytic activity. It binds to CD19 proteins on B-cell surfaces, inhibiting their function and triggering cell death. The antibody works through apoptosis and immune-mediated mechanisms, including Antibody-dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-dependent Cellular Phagocytosis (ADCP). In 2010, MorphoSys secured global exclusive rights to develop and commercialize tafasitamab from Xencor, Inc., which developed the Fc-engineered XmAb technology incorporated in the drug. In December 2024, Incyte presented pivotal findings from the Phase III inMIND trial at the ASH Annual Meeting. The study showed that combining MONJUVI with lenalidomide and rituximab significantly extended progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma, achieving both the primary PFS endpoint and key secondary measures. AZD0486 (previously TNB-486) is an innovative CD19xCD3 bispecific T-cell engager (TCE) built on an IgG4 backbone. It features a low-affinity anti-CD3 domain designed to limit cytokine release while maintaining robust T-cell-driven cytotoxicity against malignant B cells. The molecule has a silenced Fc region to avoid nonspecific binding and ADCC, while ensuring prolonged half-life for intermittent dosing. AZD0486 is currently in Phase III development for follicular lymphoma. In November 2024, at ASH 2024, AstraZeneca emphasized its growing hematology pipeline through two oral presentations on AZD0486. Phase I trial data revealed strong efficacy in R/R follicular lymphoma patients, with an overall response rate (ORR) of 96% and a complete response rate (CRR) of 85% at doses of 2.4 mg and higher. Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. DelveInsight's latest published market report, titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Incidence Cases of Follicular Lymphoma Gender-specific Cases of Follicular Lymphoma Age-specific cases of Follicular Lymphoma Stage-Specific Cases of Follicular Lymphoma Grade-Specific Cases of Follicular Lymphoma Treated Case by Line of Therapy of Follicular Lymphoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space. Related Reports Follicular Lymphoma Epidemiology Forecast Follicular Lymphoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted follicular lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Follicular Lymphoma Pipeline Follicular Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Non-Hodgkin's Lymphoma Pipeline Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Formaticum's Emilia D'Albero Ranked Top Cheesemonger in the US, Headed to the Cheese Olympics
The brand's sales manager will travel to France in September to represent Team USA in the international cheesemonger competition, Mondial du Fromage. PHILADELPHIA, June 4, 2025 /PRNewswire-PRWeb/ -- Formaticum, the leading provider of professional cheese storage solutions, is proud to announce that Emilia D'Albero, the company's national sales and marketing manager, has been named the top cheesemonger in the U.S. Following her recent win at a national competition, D'Albero will travel to France this September to represent Team USA at the prestigious Mondial du Fromage, often referred to as the "Cheese Olympics." D'Albero is part of the first all-women Team USA chosen to compete. Held every two years in Tours, France, the Mondial du Fromage brings together the world's most skilled cheesemongers to compete in a series of rigorous challenges that test their knowledge, technique and passion for cheese. D'Albero's upcoming participation marks a major milestone in her career and a proud moment for the U.S. cheese community. "This is an incredible honor, not just for me, but for everyone working to elevate cheese appreciation and education in the U.S., like Formaticum does every day," said D'Albero."The spirit of teamwork and camaraderie first drew me to this competition. I entered for the fun and the challenge, so standing here now feels surreal. I'm deeply grateful." The Mondial du Fromage is scheduled for Sept. 14 through 16. In the lead-up to the competition, D'Albero will train under the expert guidance of third-generation cheesemonger Adam Moskowitz, aiming to bring home gold for Team USA. "Formaticum congratulates Emilia on her incredible achievement and is honored to support her journey to the international stage," said Mark Goldman, Owner & Founder of Formaticum. "Her dedication, passion and commitment to the craft of cheesemongering embody everything we stand for. We're proud to be part of a community that celebrates excellence, education and the joy of cheese, and we look forward to seeing all she will accomplish next." For more information, visit About Formaticum: Formaticum cheese storage products preserve the essence of cheese so you can enjoy its true taste in all its glory. Its cheese storage paper and bags ensure proper storage, while wrapping cheese leftovers for prolonged freshness, and allow cheese lovers to indulge in the highest quality cheese until the last piece, reducing food waste. Media Contact Leah Cybulski, ChicExecs PR, 7084268730, Leah@ View original content to download multimedia: SOURCE Formaticum Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Markem-Imaje Launches New Black Ink for the Beverage Industry
DOWNERS GROVE, Ill., June 4, 2025 /PRNewswire/ -- Markem-Imaje, part of Dover (NYSE: DOV) and a global provider of end-to-end supply chain solutions and industrial marking and coding systems, today announced the launch of MB2253, a new black MEK ink specifically formulated for the beverage market. This innovative product meets stringent industry regulations, helping ensure safety and compliance for both producers and consumers. Designed for versatility, MB2253 excels in marking a wide variety of beverage substrates, including plastics, metals, glass and returnable glass bottles. It provides durable codes with excellent adhesion. Moreover, it withstands extreme icy condensation and water immersion, making it ideal for various beverage packaging environments. One of the standout features of MB2253 is its remarkable alkali solubility. It matches the lifecycle of returnable glass bottles and withstands sodium hydroxide (NaOH) solutions at concentrations up to 2.5%, ensuring that the ink remains intact. Safety is a top priority at Markem-Imaje. MB2253 is compliant with indirect food contact legislation, bringing peace of mind to end users and supporting security for producers. Formulated and manufactured in a Grade A BRC Global Standard-certified plant, the ink is produced in accordance with the "EuPIA Guideline on Printing Inks applied to the non-food contact surface of food packaging materials and articles." In addition, all materials used in MB2253 comply with: Swiss Ordinance 817.023.21 on materials and articles intended to come into contact with foodstuffs (version 2.1 of December 2020). FDA Title 21 CFR of the U.S. Code of Federal Regulations, which addresses "indirect" food additives. MB2253 is available for use with a range of continuous inkjet printers, including the 9750, 9750+, 9750 Xp, 9750 Xp+, and 9712. Please check availability in your country. About Markem-Imaje: Markem-Imaje, a wholly owned subsidiary of the US-based Dover Corporation is a trusted world manufacturer of product identification and traceability solutions, offering a full line of reliable and innovative inkjet, thermal transfer, laser, and print and apply label systems. Markem-Imaje provides global reach to over 50,000 customers with 30 subsidiaries, 6 technology centers, several equipment repair centers and manufacturing plants with the most comprehensive marking and coding portfolio available in the marketplace. Visit for further information. About Dover: Dover is a diversified global manufacturer and solutions provider with annual revenue of over $7 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at Markem-Imaje Contact:Viktor Hermansson+34 627 80 86 10vhermansson@ Dover Media Contact:Adrian Sakowicz, VP, Communications (630) 743-5039 asakowicz@ Dover Investor Contact:Jack Dickens, VP, Investor Relations(630) 743-2566jdickens@ View original content to download multimedia: SOURCE Dover Sign in to access your portfolio
